Effects of Anti-dementia Drugs on Morphine-Induced Somnolence

被引:3
|
作者
Ishida, Takayuki [1 ]
Suga, Asami [1 ]
Akagi, Masaaki [2 ]
Kamei, Chiaki [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Med Pharmacol, Kita Ku, Okayama 7008530, Japan
[2] Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Pharmacol, Yamashiro, Tokushima 7708514, Japan
关键词
morphine; opioid; anti-dementia drug; methylphenidate; somnolence; VENTRAL TEGMENTAL AREA; SLEEP-DISTURBED RATS; RECEPTORS; STATE; BEHAVIOR; NEURONS; ACID; PAIN; MICE;
D O I
10.1248/bpb.32.1862
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study was undertaken to investigate the characteristics of morphine in rat sleep patterns and also the effects of donepezil and memantine on somnolence caused by morphine. Electrodes were chronically implanted into the cortex and dorsal neck muscle of rats for electroencephalogram (EEG) and electromyogram (EMG) recordings, respectively. EEG and EMG were recorded with an electroencephalograph. SleepSigh ver.2.0, was used to analyse the sleep-wake state. Total times of wakefulness, non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep were measured from 10:00 to 16:00. Morphine at a high dose caused a significant decrease in sleep latency and total REM sleep time, although the drug at low doses caused significant increases in sleep latency and total awake time, and a significant decrease in NREM sleep time. Donepezil, memantine and methylphenidate antagonized the decrease in sleep latency caused by morphine. From these findings, it can be concluded that morphine caused somnolence, and donepezil and memantine are useful for somnolence caused by morphine, similar to methylphenidate.
引用
收藏
页码:1862 / 1865
页数:4
相关论文
共 50 条
  • [31] Lifestyle improvement or anti-dementia drugs in Alzheimer's disease
    Niwa, Fumitoshi
    Mizuno, Toshiki
    Nakagawa, Masanori
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 925 - 925
  • [32] What is new in the methods to develop new anti-dementia drugs
    Allain, H.
    Bentue-Ferrer, D.
    Belliard, S.
    Reymann, J. M.
    Merienne, M.
    Tribut, O.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 53 - 53
  • [33] Statistical treatment of withdrawal in trials of anti-dementia drugs - Reply
    Doody, Rachelle
    Seely, Lynn
    Thomas, Ronald
    Sano, Mary
    Aisen, Paul
    [J]. LANCET, 2008, 372 (9647): : 1383 - 1383
  • [34] EFFECT OF ADRENERGIC-DRUGS ON MORPHINE-INDUCED HYPERGLYCEMIA
    CLISSIOUNIS, N
    [J]. LIFE SCIENCES, 1979, 25 (04) : 391 - 394
  • [35] ENHANCEMENT OF MORPHINE-INDUCED HYPERACTIVITY BY ANTIHISTAMINIC DRUGS IN MICE
    SANSONE, M
    CASTELLANO, C
    DAMATO, FR
    [J]. ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 1986, 284 (02): : 239 - 245
  • [36] Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs
    Voshaar, RCO
    Burns, A
    Rikkert, MGMO
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 21 (01) : 29 - 31
  • [37] ENHANCEMENT OF MORPHINE-INDUCED ANALGESIA AND ATTENUATION OF MORPHINE-INDUCED SIDE-EFFECTS BY COCAINE IN RATS
    KAUPPILA, T
    MECKE, E
    PERTOVAARA, A
    [J]. PHARMACOLOGY & TOXICOLOGY, 1992, 71 (03): : 173 - 178
  • [38] Development of anti-dementia drugs for Alzheimer's disease: Present and future
    Nabeshima, T
    Yamada, K
    [J]. MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 223 - 228
  • [39] No evidence exists that "anti-dementia" drugs modify disease or improve outcome
    Gordon, Peter J.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [40] Observational cohort study: deprivation and access to anti-dementia drugs in the UK
    Cooper, Claudia
    Lodwick, Rebecca
    Walters, Kate
    Raine, Rosalind
    Manthorpe, Jill
    Iliffe, Steve
    Petersen, Irene
    [J]. AGE AND AGEING, 2016, 45 (01) : 148 - 154